2. Signaling Pathways
  3. GPCR/G Protein
  4. Platelet-activating Factor Receptor (PAFR)

Platelet-activating Factor Receptor (PAFR)

The platelet-activating factor receptor (PAFR) is a G-protein-coupled receptor involved in both normal physiological and numerous pathophysiological processes. PAFR responds to platelet-activating factor (PAF), a phospholipid mediator of cell-to-cell communication that exhibits diverse physiological effects. Stimulation of the PAFR via binding of platelet-activating factor (PAF) elicits diverse and potent biological activities and plays a profound role in acute inflammation, allergic disorders, endotoxic shock, and anaphylaxis. PAF is a potent and versatile mediator of inflammation that is produced by numerous cell types and tissues, and particularly by leukocytes.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N11932
    Piperulin A
    		Inhibitor
    Piperulin A is a potent inhibitor of PAFR. Piperulin A inhibits the specific binding of PAFR on isolated rabbit platelet plasma membranes with an IC50 of 7.3 μM.
    Piperulin A
  • HY-N3054
    Pinusolidic acid
    		Inhibitor
    Pinusolidic acid is a platelet-activating factor (PAF) inhibitor with an IC50 of 23 μM.
    Pinusolidic acid
  • HY-108634R
    Apafant (Standard)
    		Antagonist
    Apafant (Standard) is the analytical standard of Apafant (HY-108634). This product is intended for research and analytical applications. Apafant (WEB 2086), a chemical probe, is a potent platelet-activating factor (PAF) antagonist, inhibits PAF binding to human PAF receptors with a Ki of 9.9 nM. Apafant increases the gene expression of PAF-r, α-globin, β-globin, decreases the c-myb gene expression. Apafant shows a protective effect on alkyl-PAF-mediated lethalit.
    Apafant (Standard)
  • HY-N3055
    Pinusolide
    		Antagonist 99.93%
    Pinusolide is an AMPK activator and PAF receptor antagonist. Pinusolide activates AMPK, phosphorylates ACC, enhances IRS-1 tyrosine phosphorylation, boosts glucose uptake, and modulates insulin signaling. Pinusolide inhibits caspase-3/7 activation, intracellular calcium elevation, reactive oxygen species overproduction, lipid peroxidation, and tumor cell proliferation. Pinusolide stabilizes superoxide dismutase activity, reduces apoptotic hallmarks, induces mitochondrial pathway apoptosis, and triggers DNA fragmentation. Pinusolide can be used for the research of type 2 diabetes, neurodegenerative diseases, acute lymphoblastic leukemia, acute myeloid leukemia, and Burkitt lymphoma.
    Pinusolide
  • HY-N14932
    Aggreceride A
    		Inhibitor
    Aggreceride A is a platelet aggregation inhibitor. Aggreceride A shows an inhibitory activity against aggregation induced by Adenosine 5'-diphosphate (ADP) (HY-W010918), Arachidonic acid (HY-109590) and PAF (platelet activating factor), but was less active against aggregation induced by collagen.
    Aggreceride A
  • HY-123505
    Dersalazine sodium
    		Antagonist
    Dersalazine (sodium) is a platelet-activating factor (PAF) antagonist. Dersalazine (sodium) can exert intestinal anti-inflammatory activity in rodent colitis models by downregulating IL-17 expression.
    Dersalazine sodium
  • HY-122126
    BN 52111
    		Antagonist
    BN 52111 is a potent platelet-activating factor (PAF) receptor antagonist.
    BN 52111
  • HY-133003
    L662,025
    		Antagonist
    L662,025 is a specific, photolabile and irreversible Platelet-activating factor (PAF-receptor) antagonist, with IC50 values of 5.6 μM (platelet aggregation) and 1 μM (receptor binding), respectively.
    L662,025
  • HY-N14933
    Aggreceride B
    		Inhibitor
    Aggreceride B is a platelet aggregation inhibitor. Aggreceride B shows an inhibitory activity against aggregation induced by Adenosine 5'-diphosphate (ADP) (HY-W010918), Arachidonic acid (HY-109590) and PAF (platelet activating factor), but was less active against aggregation induced by collagen.
    Aggreceride B
  • HY-101833R
    YM-264 (Standard)
    YM-264 (Standard) is the analytical standard of YM-264 (HY-101833). This product is intended for research and analytical applications. YM-264 is a selective, potent and orally active platelet-activating factor (PAF) antagonist with a pKi value of 8.85 for rabbit platelet membranes.
    YM-264 (Standard)
  • HY-117636
    (Rac)-L-659989
    		Antagonist
    (Rac)-L-659989 is the racemate of L-659989 (HY-121394). L-659989 s an orally active, extremely potent, selective and competitive platelet activating factor (PAF) receptor antagonist.
    (Rac)-L-659989
  • HY-119035
    R-75317
    		Antagonist
    R-75317 is a specific platelet-activating factor (PAF) antagonist. R-75317 can prevent the decline in creatinine clearance (Ccr) in a rat model of glomerulonephritis induced by the injection of antibodies extracted from rabbits against rat glomerular basement membrane (GBM) antigens, delay the onset of proteinuria, and improve glomerular hypertrophy, mesangial matrix proliferation, and interstitial fibrosis. R-75317 may be useful in the study of glomerulonephritis.
    R-75317
  • HY-N15271
    Oxopurpureine
    Oxopurpureine is an oxoaporphine with antiplatelet aggregation activity. Oxopurpureine inhibits collagen, thrombin and arachidonic acid-induced platelet aggregation and can be utilized in relevant research.
    Oxopurpureine
  • HY-N11920
    Kadsurenin B
    		Antagonist
    Kadsurenin B is a PAF (platelet-activating factor) antagonist with neuroprotective activity. Kadsurenin B has a wide range of pharmacological research potential, such as antibacterial, anti-inflammatory, neuroprotective, antioxidant, antiplatelet aggregation, cytotoxic, antiparasitic, etc.
    Kadsurenin B
  • HY-19121
    TCV-309
    		Antagonist
    TCV-309 is an antagonist for platelet activating factor (PAF). TCV-309 improves the left ventricular function during ischemia-reperfusion (77.6% recover at 1 μM), protects the cardiac function.
    TCV-309
  • HY-176466
    ST-899
    		Agonist
    ST-899 is a novel platelet-activating factor (PAF) receptor antagonist. ST-899 can significantly reduce the mortality of mice with endotoxin (LPS)-induced shock. ST-899 can significantly inhibit the increase in serum tumor necrosis factor (TNF) levels induced by LPS, but has no effect on interleukin-6 (IL-6). The regulatory mechanism of ST-899 is to block the positive feedback loop between PAF and TNF, thereby reducing the inflammatory response. ST-899 can be used to study inflammatory diseases such as septic shock.
    ST-899
  • HY-134235
    PAF C-16 carboxylic acid
    PAF C-16 carboxylic acid (Acetyl-CPGPC) is a phospholipid that possesses haptenic activity causing production of antibodies reactive with platelet-activating factor (PAF).
    PAF C-16 carboxylic acid
  • HY-101594
    Tulopafant
    Tulopafant is a platelet activating factor (PAF) antagonist.
    Tulopafant
  • HY-19097
    Ro-24-4736
    Ro 24-4736 is a potent, selective, p.o.-active platelet-activating factor (PAF) antagonist with a long duration of action. Ro-24-4736 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Ro-24-4736
  • HY-19084
    Ro-24-0238
    Ro-24-0238 is an antagonist of platelet activating factor (PAF) and inhibitor of thromboxane synthesis, used for lessening the inflammation and damage resulting from a local release of PAF.
    Ro-24-0238
Cat. No. Product Name / Synonyms Application Reactivity